Albert David Limited

ALBERTDAVD

INE155C01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:51 2024-05-31 am EDT			5-day change	1st Jan Change
1,114 ^INR	+0.79%		-4.20%	+14.17%

May. 13	Albert David Limited Announces Executive Changes, Effective June 1, 2024	CI
May. 13	Albert David Limited Recommends Final Dividend for the Year Ended on March 31, 2024	CI

Albert David Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024

May 13, 2024 at 05:04 am EDT

Albert David Limited reported earnings results for the fourth quarter ended March 31, 2024. For the fourth quarter, the company reported sales was INR 890.58 million compared to INR 814.2 million a year ago. Revenue was INR 995 million compared to INR 814.29 million a year ago.

Net income was INR 129.13 million compared to INR 37.35 million a year ago. Basic earnings per share from continuing operations was INR 22.63 compared to INR 6.54 a year ago. Diluted earnings per share from continuing operations was INR 22.63 compared to INR 6.54 a year ago.

Latest news about Albert David Limited

Albert David Limited Announces Executive Changes, Effective June 1, 2024	May. 13	CI
Albert David Limited Recommends Final Dividend for the Year Ended on March 31, 2024	May. 13	CI
Albert David Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 13	CI
Albert David Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 13	CI
Albert David Limited Announces Resignation of Abhishek Seth as Company Secretary & Compliance Officer, Effective May 31, 2024	May. 04	CI
Albert David Limited Announces Board Retirement	Mar. 31	CI
Albert David Limited Announces Management Changes	Mar. 14	CI
Albert David Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 05	CI
Albert David Limited Announces Resignation of A. B. Chakrabartty as Company Secretary and Compliance Officer Cum Legal Head of the Company	Nov. 22	CI
Albert David Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Albert David to Invest INR6 Million in Solar Power Company	23-09-08	MT
Sunsure Solarpark Five Private Limited announced that it expects to receive INR 6.125 million in funding from Albert David Limited	23-09-07	CI
Albert David Limited Approves Dividend for the Financial Year Ended March 31, 2023	23-08-10	CI
Albert David Limited Announces Board Changes	23-08-10	CI
Albert David Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Albert David Limited Recommends Dividend for the Financial Year 2022-2023	23-05-19	CI
Albert David Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-19	CI
CARE Upgrades Rating on Albert David's Long-term Bank Financing; Outlook Stable	23-03-30	MT
Albert David Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Albert David Names New CEO	23-02-05	MT
Albert David Limited Appoints Mr. A B Chakrabartty as the Company Secretary & Compliance Officer Cum Legal Head of the Company	23-02-04	CI
Albert David Limited Appoints Mr. Umesh Kunte as the Chief Executive Officer, Effective on February 06, 2023	23-02-04	CI
Albert David Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-12	CI
Albert David Limited Announces Reconstitution of Committees of the Board of Directors	22-09-13	CI
Albert David CEO Resigns	22-09-08	MT

Chart Albert David Limited

Duration

Period

More charts

Company Profile

Albert David Limited is engaged in manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs by way of domestic sale or export. The Company offers its products under various categories, which includes parenteral, oral/enteral, topical agents and vision care. Its parenteral consists of amino acids infusion, antimicrobial, anti-leishmaniasis (kalazar), hemostat, neurotropic vitamin, and placenta extract. Its oral/enteral consists of amino acids oral, anthelmintic, anti-microbial, anti ulcerants, anti-vertigo, appetite stimulants, anti-tubercular, hematinic, oral vitamin b complex and expectorant / cough syrup. Its topical agents consist of non-steroidal anti-inflammatory drugs (NSAID). Its vision care consists of anti-glaucoma, anti-infective, tear substitutes and anti-infective with NSAID. It has presence in Southeast Asia, Africa, countries of Middle - East, Europe, United States of America, and Latin America.

Sector

Pharmaceuticals

Calendar

2024-08-01 - Ex-dividend day for final dividend

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ALBERT DAVID LIMITED	+14.17%	76.21M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B